Drug Trial Radar · NCT06308874
Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females
Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 2, 2023
Primary completion
Feb 17, 2023
Study completion Feb 17, 2023
Sponsor
- Lead sponsor
- J2H BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 19 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
\- Objectives: Primary objective\_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects. Secondary objective\_To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics after single oral administration of the IP, J2H-1702 in healthy female subjects.
Conditions
- Non-alcoholic Steatohepatitis
Interventions
Amg dose administration groupDrug
Orally, Amg tablet single administration
Amg dose administration group- PlaceboDrug
Orally, Placebo Amg tablet single administration
Bmg dose administration groupDrug
Orally, Bmg tablet single administration
Bmg dose administration group- PlaceboDrug
Orally, Placebo Bmg tablet single administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours (After IP administration)
- EmaxTime frame: -1day 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours, 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours (After IP administration)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
J2H Biotech
Suwon, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.